These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 34511333)

  • 1. Long-Term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia.
    Sajatovic M; Finkbeiner S; Wilhelm A; Barkay H; Chaijale N; Gross N; Gordon MF
    Am J Geriatr Psychiatry; 2022 Mar; 30(3):360-371. PubMed ID: 34511333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal clinically important change in Abnormal Involuntary Movement Scale score in tardive dyskinesia as assessed in pivotal trials of deutetrabenazine.
    Hauser RA; Barkay H; Wilhelm A; Wieman M; Savola JM; Gordon MF
    Parkinsonism Relat Disord; 2022 Apr; 97():47-51. PubMed ID: 35299070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study.
    Hauser RA; Barkay H; Fernandez HH; Factor SA; Jimenez-Shahed J; Gross N; Marinelli L; Wilhelm A; Alexander J; Gordon MF; Savola JM; Anderson KE
    Front Neurol; 2022; 13():773999. PubMed ID: 35280262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Anderson KE; Stamler D; Davis MD; Factor SA; Hauser RA; Isojärvi J; Jarskog LF; Jimenez-Shahed J; Kumar R; McEvoy JP; Ochudlo S; Ondo WG; Fernandez HH
    Lancet Psychiatry; 2017 Aug; 4(8):595-604. PubMed ID: 28668671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.
    Fernandez HH; Factor SA; Hauser RA; Jimenez-Shahed J; Ondo WG; Jarskog LF; Meltzer HY; Woods SW; Bega D; LeDoux MS; Shprecher DR; Davis C; Davis MD; Stamler D; Anderson KE
    Neurology; 2017 May; 88(21):2003-2010. PubMed ID: 28446646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 29024264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia.
    Fernandez HH; Stamler D; Davis MD; Factor SA; Hauser RA; Jimenez-Shahed J; Ondo WG; Jarskog LF; Woods SW; Bega D; LeDoux MS; Shprecher DR; Anderson KE
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1317-1323. PubMed ID: 31296586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
    Solmi M; Pigato G; Kane JM; Correll CU
    Drug Des Devel Ther; 2018; 12():1215-1238. PubMed ID: 29795977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deutetrabenazine Provides Long-Term Benefit for Tardive Dyskinesia Regardless of Underlying Condition and Dopamine Receptor Antagonist Use: A Post Hoc Analysis of the 3-Year, Open-Label Extension Study.
    Hauser RA; Barkay H; Fernandez HH; Jimenez-Shahed J; Factor SA; Gross N; Marinelli L; Gordon MF; Barash S; Finkbeiner S; Chaijale N; Anderson KE
    J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):386-396. PubMed ID: 38901008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deutetrabenazine in the treatment of tardive dyskinesia.
    Niemann N; Jimenez-Shahed J
    Neurodegener Dis Manag; 2019 Apr; 9(2):59-71. PubMed ID: 30702019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
    McIntyre RS; Calabrese JR; Nierenberg AA; Farahmand K; Yonan C; Siegert S; Burke J
    J Affect Disord; 2019 Mar; 246():217-223. PubMed ID: 30583148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of valbenazine on tardive dyskinesia in older and younger patients.
    Sajatovic M; Alexopoulos GS; Burke J; Farahmand K; Siegert S
    Int J Geriatr Psychiatry; 2020 Jan; 35(1):69-79. PubMed ID: 31617235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia and Chorea Associated with Huntington Disease.
    Frank S; Anderson KE; Fernandez HH; Hauser RA; Claassen DO; Stamler D; Factor SA; Jimenez-Shahed J; Barkay H; Wilhelm A; Alexander JK; Chaijale N; Barash S; Savola JM; Gordon MF; Chen M
    Neurol Ther; 2024 Jun; 13(3):655-675. PubMed ID: 38557959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
    Golsorkhi M; Koch J; Pedouim F; Frei K; Bondariyan N; Dashtipour K
    Tremor Other Hyperkinet Mov (N Y); 2024; 14():13. PubMed ID: 38497033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia.
    Marder SR; Singer C; Lindenmayer JP; Tanner CM; Comella CL; Verghese C; Jimenez R; Liang GS; Burke J; OʼBrien CF
    J Clin Psychopharmacol; 2019; 39(6):620-627. PubMed ID: 31688452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia.
    Aggarwal S; Serbin M; Yonan C
    J Comp Eff Res; 2019 Oct; 8(13):1077-1088. PubMed ID: 31464152
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of valbenazine compared with deutetrabenazine for the treatment of tardive dyskinesia.
    Ganz ML; Chavan A; Dhanda R; Serbin M; Yonan C
    J Med Econ; 2021; 24(1):103-113. PubMed ID: 33393412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.
    Khorassani F; Luther K; Talreja O
    Am J Health Syst Pharm; 2020 Jan; 77(3):167-174. PubMed ID: 31974564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.